Shots:

• Myovant & Pfizer will jointly develop & commercialize ORGOVYX (relugolix) in advanced prostate cancer & if approved- relugolix combination tablet in women’s health in the US & Canada. Myovant will receive ~$4.2B including $650M upfront- $200M in regulatory milestones for FDA approvals for relugolix combination tablet in women’s health- and tiered sales milestones upon reaching certain thresholds up to $2.5 billion in net sales for prostate cancer and women’s health indications
• Additionally- Pfizer will receive an exclusive option to commercialize relugolix in oncology outside the US and Canada- excluding certain Asian countries and if Pfizer exercises the option to commercialize relugolix in oncology- Myovant will receive $50M and is eligible to receive double-digit royalties.
• Relugolix is a GnRH receptor antagonist that reduces testicular testosterone- a hormone known to stimulate the growth of prostate cancer- and ovarian estradiol. Relugolix (120mg) is FDA approved as ORGOVYX for adult patients with advanced prostate cancer

 ­ Ref: GlobeNewswire | Image: Myovant